281 related articles for article (PubMed ID: 25855377)
1. Decreased ferroportin promotes myeloma cell growth and osteoclast differentiation.
Gu Z; Wang H; Xia J; Yang Y; Jin Z; Xu H; Shi J; De Domenico I; Tricot G; Zhan F
Cancer Res; 2015 Jun; 75(11):2211-21. PubMed ID: 25855377
[TBL] [Abstract][Full Text] [Related]
2. Ferroportin downregulation promotes cell proliferation by modulating the Nrf2-miR-17-5p axis in multiple myeloma.
Kong Y; Hu L; Lu K; Wang Y; Xie Y; Gao L; Yang G; Xie B; He W; Chen G; Wu H; Wu X; Zhan F; Shi J
Cell Death Dis; 2019 Aug; 10(9):624. PubMed ID: 31423010
[TBL] [Abstract][Full Text] [Related]
3. Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation.
Boissy P; Andersen TL; Abdallah BM; Kassem M; Plesner T; Delaissé JM
Cancer Res; 2005 Nov; 65(21):9943-52. PubMed ID: 16267019
[TBL] [Abstract][Full Text] [Related]
4. Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis
Wang L; Fang B; Fujiwara T; Krager K; Gorantla A; Li C; Feng JQ; Jennings ML; Zhou J; Aykin-Burns N; Zhao H
J Biol Chem; 2018 Jun; 293(24):9248-9264. PubMed ID: 29724825
[TBL] [Abstract][Full Text] [Related]
5. Expression of alternative transcripts of ferroportin-1 during human erythroid differentiation.
Cianetti L; Segnalini P; Calzolari A; Morsilli O; Felicetti F; Ramoni C; Gabbianelli M; Testa U; Sposi NM
Haematologica; 2005 Dec; 90(12):1595-606. PubMed ID: 16330432
[TBL] [Abstract][Full Text] [Related]
6. Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA).
Hecht M; von Metzler I; Sack K; Kaiser M; Sezer O
Exp Cell Res; 2008 Mar; 314(5):1082-93. PubMed ID: 18053985
[TBL] [Abstract][Full Text] [Related]
7. Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease.
Pennisi A; Li X; Ling W; Khan S; Gaddy D; Suva LJ; Barlogie B; Shaughnessy JD; Aziz N; Yaccoby S
Br J Haematol; 2009 Jun; 145(6):775-87. PubMed ID: 19388929
[TBL] [Abstract][Full Text] [Related]
8. Extracellular Iron is a Modulator of the Differentiation of Osteoclast Lineage Cells.
Xie W; Lorenz S; Dolder S; Hofstetter W
Calcif Tissue Int; 2016 Mar; 98(3):275-83. PubMed ID: 26615413
[TBL] [Abstract][Full Text] [Related]
9. Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression.
Gowda PS; Wildman BJ; Trotter TN; Xu X; Hao X; Hassan MQ; Yang Y
Mol Cancer Res; 2018 Jul; 16(7):1138-1148. PubMed ID: 29592898
[TBL] [Abstract][Full Text] [Related]
10. Expression of iron transport proteins divalent metal transporter-1, Ferroportin-1, HFE and transferrin receptor-1 in human monocyte-derived dendritic cells.
Brinkmann M; Teuffel R; Laham N; Ehrlich R; Decker P; Lemonnier FA; Pascolo S
Cell Biochem Funct; 2007; 25(3):287-96. PubMed ID: 16927405
[TBL] [Abstract][Full Text] [Related]
11. Expression and function of ferroportin 1 in O-2A progenitor cells.
Lin Q; Feng J; Zhao X; Zhang G; Wang W
Anat Rec (Hoboken); 2013 Jan; 296(1):108-16. PubMed ID: 23117987
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of transferrin receptor-1 induces cholangiocarcinoma progression via induction of labile iron pool.
Jamnongkan W; Thanan R; Techasen A; Namwat N; Loilome W; Intarawichian P; Titapun A; Yongvanit P
Tumour Biol; 2017 Jul; 39(7):1010428317717655. PubMed ID: 28671021
[TBL] [Abstract][Full Text] [Related]
13. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
14. Pinpointing a Factor in Myeloma Bone Disease.
Cancer Discov; 2016 Nov; 6(11):1201-1202. PubMed ID: 27658717
[TBL] [Abstract][Full Text] [Related]
15. Expression of ferroportin1, hephaestin and ceruloplasmin in rat heart.
Qian ZM; Chang YZ; Leung G; Du JR; Zhu L; Wang Q; Niu L; Xu YJ; Yang L; Ho KP; Ke Y
Biochim Biophys Acta; 2007 May; 1772(5):527-32. PubMed ID: 17383861
[TBL] [Abstract][Full Text] [Related]
16. An osteoprotegerin-like peptidomimetic inhibits osteoclastic bone resorption and osteolytic bone disease in myeloma.
Heath DJ; Vanderkerken K; Cheng X; Gallagher O; Prideaux M; Murali R; Croucher PI
Cancer Res; 2007 Jan; 67(1):202-8. PubMed ID: 17210700
[TBL] [Abstract][Full Text] [Related]
17. Myeloid zinc-finger 1 (MZF-1) suppresses prostate tumor growth through enforcing ferroportin-conducted iron egress.
Chen Y; Zhang Z; Yang K; Du J; Xu Y; Liu S
Oncogene; 2015 Jul; 34(29):3839-47. PubMed ID: 25284586
[TBL] [Abstract][Full Text] [Related]
18. Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions.
Boissy P; Andersen TL; Lund T; Kupisiewicz K; Plesner T; Delaissé JM
Leuk Res; 2008 Nov; 32(11):1661-8. PubMed ID: 18394701
[TBL] [Abstract][Full Text] [Related]
19. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
20. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
